Unit of Genetic Epidemiology, Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
PLoS One. 2012;7(8):e42380. doi: 10.1371/journal.pone.0042380. Epub 2012 Aug 7.
The 6q25.1 locus was first identified via a genome-wide association study (GWAS) in Chinese women and marked by single nucleotide polymorphism (SNP) rs2046210, approximately 180 Kb upstream of ESR1. There have been conflicting reports about the association of this locus with breast cancer in Europeans, and a GWAS in Europeans identified a different SNP, tagged here by rs12662670. We examined the associations of both SNPs in up to 61,689 cases and 58,822 controls from forty-four studies collaborating in the Breast Cancer Association Consortium, of which four studies were of Asian and 39 of European descent. Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Case-only analyses were used to compare SNP effects in Estrogen Receptor positive (ER+) versus negative (ER-) tumours. Models including both SNPs were fitted to investigate whether the SNP effects were independent. Both SNPs are significantly associated with breast cancer risk in both ethnic groups. Per-allele ORs are higher in Asian than in European studies [rs2046210: OR (A/G) = 1.36 (95% CI 1.26-1.48), p = 7.6 × 10(-14) in Asians and 1.09 (95% CI 1.07-1.11), p = 6.8 × 10(-18) in Europeans. rs12662670: OR (G/T) = 1.29 (95% CI 1.19-1.41), p = 1.2 × 10(-9) in Asians and 1.12 (95% CI 1.08-1.17), p = 3.8 × 10(-9) in Europeans]. SNP rs2046210 is associated with a significantly greater risk of ER- than ER+ tumours in Europeans [OR (ER-) = 1.20 (95% CI 1.15-1.25), p = 1.8 × 10(-17) versus OR (ER+) = 1.07 (95% CI 1.04-1.1), p = 1.3 × 10(-7), p(heterogeneity) = 5.1 × 10(-6)]. In these Asian studies, by contrast, there is no clear evidence of a differential association by tumour receptor status. Each SNP is associated with risk after adjustment for the other SNP. These results suggest the presence of two variants at 6q25.1 each independently associated with breast cancer risk in Asians and in Europeans. Of these two, the one tagged by rs2046210 is associated with a greater risk of ER- tumours.
6q25.1 基因座最初是通过在中国女性中进行的全基因组关联研究(GWAS)发现的,该基因座由单核苷酸多态性(SNP)rs2046210 标记,位于 ESR1 上游约 180 Kb 处。关于该基因座与欧洲人乳腺癌的相关性存在相互矛盾的报告,欧洲人的 GWAS 确定了另一个 SNP,这里标记为 rs12662670。我们在来自乳腺癌症协会合作组织的 44 项研究中,对多达 61689 例病例和 58822 例对照进行了这两个 SNP 的关联研究,其中 4 项研究为亚洲人群,39 项为欧洲人群。我们使用逻辑回归来估计比值比(OR)和 95%置信区间(CI)。使用病例仅分析比较了雌激素受体阳性(ER+)与阴性(ER-)肿瘤中 SNP 的作用。拟合包含两个 SNP 的模型以研究 SNP 作用是否独立。在两个种族群体中,这两个 SNP 均与乳腺癌风险显著相关。亚洲研究中的每个等位基因的 OR 均高于欧洲研究[rs2046210:OR(A / G)= 1.36(95%CI 1.26-1.48),p = 7.6×10(-14);rs12662670:OR(G / T)= 1.29(95%CI 1.19-1.41),p = 1.2×10(-9)]。欧洲人中的 SNP rs12662670:OR(G / T)= 1.09(95%CI 1.07-1.11),p = 6.8×10(-18);rs2046210:OR(A / G)= 1.07(95%CI 1.04-1.1),p = 1.3×10(-7),p(异质性)= 5.1×10(-6)]。相比之下,在这些亚洲研究中,肿瘤受体状态没有明显的差异关联证据。调整其他 SNP 后,每个 SNP 都与风险相关。这些结果表明,在亚洲人和欧洲人中,6q25.1 处的两个变体均独立与乳腺癌风险相关。其中,rs2046210 标记的变体与 ER-肿瘤的风险增加有关。